Blog

What PBM reform proposals would change for patients and what critics say

Five common ideas for changing how pharmacy benefit managers work, side by side: what each would do at the counter and what supporters and the industry say.

Almost every proposal to change how pharmacy benefit managers work comes down to one question: who should be paid for what, and who gets to see the numbers? Five ideas come up again and again, in Congress, in federal agency rules and in state legislatures. They overlap, they have different supporters, and none of them would change your copay on the day it passes. This post sets them side by side, describes what each would do and what each side says about it, and ends with what to watch for if you are trying to guess how a proposal might reach your pharmacy counter.

Nothing here is an endorsement. The ideas are described as proposals, because what is law, what is pending and what has been rewritten changes often. Where a date matters, it is stated, and where you should check for the current status, the post says so.

The short version of how PBMs get paid

A pharmacy benefit manager (PBM) is a company that runs the drug benefit for a health plan or an employer. It builds a pharmacy network, negotiates with drug makers and pharmacies, processes claims at the counter and often runs its own mail-order and specialty pharmacies. The what pharmacy benefit managers do and why they matter covers the job in full. For this post, the important part is the money.

A PBM can earn money in several places:

  • Rebates. Drug makers pay a drug rebate to have a drug placed on a plan's formulary, or on a better tier. The PBM usually keeps part and passes part to the plan sponsor.
  • Fees. Drug makers and plans may pay administrative or service fees, sometimes as a percentage of a drug's list price.
  • Spread. The PBM may charge a plan more for a drug than it reimburses the pharmacy, and keep the difference.
  • Its own pharmacies. A PBM that owns a mail-order pharmacy or specialty pharmacy earns the pharmacy margin as well.

Critics say these arrangements reward high list prices and steer patients to pharmacies the PBM owns. PBMs and their trade groups say they hold down costs by negotiating discounts that drug makers would not otherwise give, and that most savings are passed on to the plans that hire them. Both statements can be partly true at once, which is why the proposals differ so much.

The five ideas side by side

Proposal What it would do What it could mean at the counter What supporters say What critics and the PBM industry say
Delinking compensation from list price Pay PBMs a flat fee or a fee unrelated to a drug's price, instead of a share of rebates or list price Less reason for the PBM to prefer a high-list-price drug over a cheaper equivalent Removes an incentive to favor expensive drugs Could raise the fees plans pay up front; may reduce negotiating leverage
Rebate pass-through Require some or all rebates to go to the plan sponsor or to patients at the point of sale A coinsurance based on a lower price, if rebates are used to reduce what you pay Patients who pay a percentage of list price would share in the discount Rebate savings may be priced into premiums already; could shift costs rather than cut them
Transparency reporting Require PBMs to report what they collect and pay, to plan sponsors, regulators or both Nothing directly; it changes what sponsors and agencies can see Lets employers and regulators check what they are paying for Compliance burden; concern that disclosed contract terms weaken negotiations
Limits on pharmacy ownership Bar or restrict a PBM from owning pharmacies, or require separation Less steering to a PBM-owned mail-order or specialty pharmacy Removes a conflict of interest Could reduce coordination and convenience; integrated companies argue ownership lowers costs
Any-willing-pharmacy rules Require a plan to let any pharmacy that accepts the terms join its network More pharmacies to choose from, including small local ones Protects access, especially in rural areas Could weaken the discounts that come from narrower networks

The rest of this post takes each row in turn.

What it does. Today a PBM's income can rise when a drug's list price rises, because rebates and many fees are calculated as a share of that price. Delinking means paying the PBM in a way that does not depend on the price of the drugs it handles, such as a flat per-claim fee. The word comes from "de-linking" the PBM's income from the drug's price.

What it could change for you. In principle, a PBM paid a flat fee has no income reason to favor a drug with a higher list price and bigger rebate over a lower-priced alternative. If a plan then favors the lower-priced drug, your coinsurance, which is a percentage of the price, falls with it. If you take a drug that has no cheaper equivalent, you may see no change.

What supporters say. They argue that the current system rewards the wrong behavior, and that paying a flat fee puts the PBM's incentive in line with the patient's.

What critics say. PBM groups say rebates are the way plans capture savings, and that a flat-fee model could raise administrative costs. Some employers, who hire PBMs, say they already negotiate flat-fee contracts, so legislation is unnecessary. Others say they cannot get these contracts without a law. A fair reading is that the effect depends heavily on how a rule is written, including whether it applies to Medicare Part D, commercial plans or both.

Idea 2: rebate pass-through

What it does. Rebate pass-through proposals require some or all of the rebates a PBM collects to be passed on, either to the plan sponsor or to patients when they buy the drug.

The coinsurance problem it targets. Say a hypothetical drug has a list price of $1,000 and a rebate of $300, so the net price to the plan is $700. If the plan charges you 20% coinsurance on the list price, you pay $200. If coinsurance were calculated on the net price, you would pay $140. The $60 difference is the whole argument. (These numbers are an illustration, not a real drug.) The post Why do I pay coinsurance on a drug price my plan gets a rebate on? walks through the mechanism in more detail.

What supporters say. Patients who pay deductibles and coinsurance are the people for whom a lower price at the counter matters most, and it is unfair that those who use the most expensive drugs subsidize lower premiums for others.

What critics say. The rebate money already reduces premiums for everyone in the plan, so moving it to the point of sale would help the people using drugs and could raise premiums for everyone else. Some plans already apply rebates at the counter, and the PBM industry says that is the right approach rather than a mandate. Neither side disputes that the answer varies by plan.

Idea 3: transparency reporting

What it does. Transparency proposals require PBMs to report what they receive from drug makers, what they pay pharmacies, what they charge plans and what they keep. Reports go to the plan sponsor, to a regulator, or to both.

Why it is different from the others. It does not change any price on its own. It changes who can see what. An employer that hires a PBM often does not know how much of the plan's drug spending is rebates, fees or spread. Supporters say an employer with that information can negotiate better. Opponents say that contract terms are trade secrets and that disclosure could weaken the discounts they negotiate.

A dated federal example. On October 16, 2026, CMS published a proposed rule for the 2028 Medicare Advantage and Part D program. Among other things, the proposal includes annual reporting of PBM compensation. It had a 60-day comment period, and as of November 2026 it is a proposal, not a final rule. Check CMS.gov and the Federal Register for whether it has been finalized and what changed. The proposal says what is reported, not what Part D plans must change about your copays.

Idea 4: limits on pharmacy ownership

What it does. Some of the largest PBMs are owned by, or part of, companies that also own insurers and pharmacies. Proposals range from requiring separation between a PBM and the pharmacies it owns, to banning certain practices such as paying its own pharmacies more than competitors.

What it could change for you. You might notice it if your plan or PBM requires specialty drugs to come from one pharmacy, or gives a lower copay at a mail-order pharmacy the PBM owns. Under a separation rule, the plan's reasons for choosing one pharmacy would have to rest on price and service rather than ownership. Related issues are covered in What should I watch for if my insurer also owns doctors and a PBM?.

What supporters say. A company that decides which pharmacies are in network and also owns some of them has a conflict of interest.

What critics say. The companies argue that integration lets them coordinate care, check for drug interactions and lower costs, and that forcing a separation would be disruptive and might raise prices. This is one of the most disputed ideas on the list, and the disagreement is partly about evidence: each side points to different studies, and a reader should be wary of confident claims either way.

Idea 5: any-willing-pharmacy rules

What it does. An any-willing-pharmacy rule says that if a pharmacy is willing to accept a plan's terms, the plan has to let it in the network. Plans may now exclude pharmacies or offer a smaller "preferred" network with lower copays.

What it could change for you. More choice. A small independent or rural pharmacy might be able to fill prescriptions under your plan instead of your having to drive farther or use mail order. Many states have passed their own versions of rules on pharmacy access and PBM practices, and the details differ.

What supporters say. Independent pharmacies say they are sometimes shut out, or paid less than it costs to fill a prescription, and that when they close, patients lose access.

What critics say. Plans say narrow networks are how they win discounts from pharmacies, and that a network open to everyone has less leverage. They also say mandatory participation can mean higher costs for the plan. The question of what "the terms" are is where the fights happen: a rule that lets any pharmacy in, but on terms nobody can afford, may not help.

Why a state law may not reach your plan

Many reform ideas are first passed by states, which regulate insurance. State insurance laws generally apply to plans an insurer sells, and have a harder time reaching a self-funded plan, where an employer pays claims itself under federal rules. Courts have been asked where the line falls, and the answer depends on the specific law. If you get your coverage from a large employer, ask whether the plan is fully insured or self-funded. The self-funded vs fully insured employer plans: why it matters to you explains the difference. The state insurance department can tell you whether a particular state law applies to your plan type.

What to watch for when you read about a proposal

Headlines tend to say a bill "ends" something. These are the questions that tell you what it really does.

  1. Which market does it cover? Medicare Part D, employer plans, individual plans and Medicaid are governed by different laws. A rule for one is not a rule for all.
  2. Does it apply now, or after a delay? Many provisions start a year or more after enactment, and some depend on agency rulemaking, so there is a gap between passing and affecting you.
  3. Does it change what you pay, or only what others see? Transparency changes visibility. Pass-through and delinking may change prices, but only if plans actually use the savings to lower cost-sharing.
  4. Who pays more instead? If a change moves money from one place to another, ask where it goes. A lower coinsurance for drug users may be balanced by a higher premium.
  5. Is it a proposal, a bill that passed one chamber, a final rule or a law? Each status is different, and the reporting does not always make it clear.
  6. Is anything in it already common practice? Some employers and plans already do what a proposal would require.

What you can do now, whatever happens in Washington

You do not need to wait for reform to protect yourself from the parts of the system you can see.

Key takeaways

  • The five main ideas are delinking pay from list price, passing rebates through, requiring transparency, limiting pharmacy ownership and requiring any-willing-pharmacy networks. They address different problems and do not all change what a patient pays.
  • Supporters and the PBM industry disagree about incentives and savings, not only about politics, and each side has data it prefers. Treat any claim of a sure outcome with caution.
  • As of November 2026, a proposed CMS rule for Medicare Advantage and Part D would require annual PBM compensation reporting. It is a proposal, so check CMS.gov and the Federal Register for its status.
  • State laws may not reach self-funded employer plans, so which kind of plan you have affects which reforms could touch you.
  • Whatever passes, the steps you can take now are the same: check the formulary each year, ask for the price before you fill, and find out whether your plan counts copay-card money.

Terms used in this guide

Related guides

Latest on this topic